Industry News
Pharmaceutical Industry News
Viatris’ three-year reorganization…
Viatris' three-year reorganization will affect staffers in a range of functions including the company's commercial teams, R&D, medical affairs and manufacturing. Besides the layoffs, the drugmaker also reported a fire in India.
GSK’s every-two-month injection…
GSK's every-two-month injection kept adolescents with HIV virologically suppressed at 96 weeks, GSK's ViiV presented at the recent Conference on Retroviruses and Opportunistic Infections.
The treatment landscape for clear…
The treatment landscape for clear cell renal cell carcinoma could be due for a shake-up following dual breakthroughs from Merck’s Litespark clinical trial program for Welireg. But one critical factor could hinder these Welireg regimens
Pharma logistics are evolving and…
Pharma logistics are evolving and Frontier Scientific Solutions leads the way with a more reliable, temperature-controlled global supply chain.
AI is now routine in how people…
AI is now routine in how people search and process information, with users relying on systems interpreting intent and delivering direct responses, especially in healthcare.
After promising to sell off 7% of…
After promising to sell off 7% of its business back in November, Charles River Laboratories has delivered. The CRO is offloading its entire contract manufacturing operation and some of its European discovery service assets, which
In developing media plans to reach…
In developing media plans to reach the GLP-1-interested consumer, audio advertising may represent a “blind spot,” according to Anna Clement, director head of industry for SiriusXM Media’s pharma vertical.
When BridgeBio presented its…
When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing pressure on Attruby and provided more evidence of the drug's strong launch, possibly giving investors a
Learn about where, how, and when…
Learn about where, how, and when AI is actually making an impact on clinical development based on insights and experiences of working with pharma.
Sanofi has kicked off its…
Sanofi has kicked off its preparations for the 2026 World Cup by becoming an official backer of Boston’s involvement in the soccer showcase.
Novartis is wasting little time…
Novartis is wasting little time sketching out the radiopharmaceutical details of its $23 billion U.S. investment push. Shortly after announcing a new manufacturing facility for the class of cancer meds in Florida, the pharma giant
The company unveiled detailed…
The company unveiled detailed results from its pair of late-stage Artistry trials this week at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.
A coalition of 15 states is filing…
A coalition of 15 states is filing a lawsuit against Robert F. Kennedy Jr. and the Centers for Disease Control and Prevention, challenging their overhaul of the vaccine schedule for children in the U.S.
Amid efforts on several fronts to…
Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price.
AstraZeneca is giving Pascal…
AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty” to advance the British pharma toward an ambitious 2030 goal.
Just three months after further…
Just three months after further scaling back its support for the struggling hemophilia A gene therapy Roctavian, the company is walking away altogether by pulling the treatment from the market.
GenEdit is sailing toward the…
GenEdit is sailing toward the clinic with a new name and fresh funding. Rebranded as BreezeBio, the biotech has raised $60 million to take a drug candidate designed to restore immune tolerance in Type 1
Looking to gain an edge as its…
Looking to gain an edge as its broader obesity ambitions take shape, Pfizer has picked up the rights to a recently approved GLP-1 in China, unlocking an immediate commercial opportunity in type 2 diabetes, with
The family of a Baltimore woman…
The family of a Baltimore woman whose cells were extracted for medical research without her consent 75 years ago has settled a lawsuit with Novartis, with terms of the agreement confidential. Lawsuits the estate has
Four years after the FDA issued…
Four years after the FDA issued its most heavy-handed form of a rejection to pegzilarginase, the U.S. regulator has given the same treatment a thumbs-up. Scoring an accelerated nod is Immedica Pharma for Loargys as